Get Your FREE subscription today
Current Issues Past Issues Who We Are Resources Get Involved Glossary
 
From the Editor
Editor's Note
 
Memory News
New Memory Book
 
The Color of Risk
African-Americans are more likely to develop Alzheimer’s disease than whites. A new national program targets this dangerous disparity with community-based health education.
Go to Article >>
 
Caring for Culture
Hispanics in Milwaukee are improving services for elders with Alzheimer's disease by customizing care to cultural attitudes toward dementia and medicine.

Go to Article >>

 
Minority Report
Jennifer Manly’s research ensures that African-Americans and other racial and ethnic minorities are tested for dementia on a level playing field.
Go to Article >>
 
Memory Tip
Remembering the Future
Glossary
Tacrine
 

Tacrine is a drug used for treatment of symptoms associated with Alzheimer's disease. It was approved by the US Food and Drug Administration (FDA) in 1993 and is currently marketed under the brand name of Cognex. Tacrine was the first drug approved to treat Alzheimer's in the US; however, it can cause serious side effects including liver problems, and so its use has declined.

Tacrine works to increase the level of acetylcholine in the brain. Acetylcholine is a neurotransmitter which is important for learning and memory; one feature of AD is a reduction in brain levels of acetylcholine. Like the other currently-available AD drugs, donepezil (trade name Aricept), rivastigmine (trade name Exelon) and galantamine (trade name Reminyl), tacrine is a cholinesterase inhibitor, meaning that it acts to inhibit the enzymes which break down unused acetylcholine; the result is that existing acetylcholine survives longer and is more effective.

by Catherine E. Myers. Copyright © 2006 Memory Loss and the Brain